Curis INC 10-K annual reports

Curis, Inc. reported a net loss of $7.6 million for 2025 and raised substantial doubt about its ability to continue as a going concern, despite recent financing and ongoing clinical trials for its lead drug candidate, emavusertib.

Curis Inc. details its financial results for 2024 and provides updates on the clinical development of its lead drug candidate, emavusertib, including discussions with regulatory agencies regarding potential accelerated approval pathways.

Curis Inc.'s annual 10-K filing provides a comprehensive overview of its securities, financial performance, regulatory environment, and strategic direction, highlighting the development of emavusertib and its financial challenges.